Clinical trials: Antiviral Agents
HIV-1-infection
10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults
Many HIV-infected individuals mount a broad neutralizing serologic response 2-3 years after infection. Broadly neutralizing antibodies might play an important role in protection from acquisition of HIV infection because they can…
- Trial name
- NCT03875209
- Testing
- 10E8.4/iMab
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- David Ho
HIV Infections, Hepatitis B
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV
This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV) in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV drugs for 24 weeks, then stop taking…
- Trial name
- NCT00051090
- Testing
- Telbivudine, Lamivudine, Efavirenz
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Virus
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment…
- Trial name
- NCT02581020
- Where
- 53 sites in Japan
- Volunteers
- 344 people
- Sponsor
- AbbVie
PTSD
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement…
- Trial name
- NCT05637879
- Testing
- Glecaprevir/pibrentasvir
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- White River Junction Veterans Affairs Medical Center
HIV Infections
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection.
- Trial name
- NCT07202546
- Testing
- VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 186 people
- Sponsor
- ViiV Healthcare
Psychiatric Disorders, Cognitive Impairment
Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related
Chronic hepatitis HCV-related is the most common cause of chronic liver disease in Italy. Patients with chronic hepatitis C present a prevalence of depressive disorders higher than that of the general population; moreover, it has…
- Conditions
- Psychiatric Disorders, Cognitive Impairment, Chronic Hepatitis c
- Trial name
- NCT03313154
- Testing
- Neuropsychiatric screening
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
Covid19
Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients
The phase II clinical trial, with three arms and at rate of 10 patients per arm, received the approval of the National Committee for Ethics and Health Research.
- Trial name
- CANCOVID-19 (NCT04502342)
- Testing
- Hydroxycloroquine and Azythromycine, Cospherunate/Azythromycine, Cospherunate/Phytomedicine/Azythromycien
- Where
- Guinea
- Volunteers
- 30 people
- Sponsor
- Institute for Research and Development of Medicinal and Food Plants of Guinea
Bioequivalence
Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting…
- Trial name
- Favipiravir (NCT04406194)
- Testing
- FAVICOVIR 200 mg Film Tablet, AVIGAN 200 mg Film Tablets
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Atabay Kimya Sanayi Ticaret A.S.
Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection
Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients
This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors.
- Trial name
- PRARE-CHB (NCT07274345)
- Volunteers
- 2,000 people
- Sponsor
- Amira Mohamed Zidan
Chronic Hepatitis B
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
- Trial name
- NCT00037622
- Testing
- ACH-126, 443 (beta-L-Fd4C)
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc
Hypothesis: Intensification of current ARV regimens with maraviroc will result in more complete suppression of viral replication, particularly in the gastrointestinal mucosa with resultant reduction in markers of immune…
- Trial name
- NCT00703586
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Rockefeller University
Human Immunodeficiency Virus Type 1
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
- Trial name
- NCT00110305
- Testing
- TMC278 25 mg, TMC278 75 mg, TMC278 150 mg
- Where
- 40 sites in United States, Argentina and 12 more
- Volunteers
- 368 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis B, Chronic
Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients
The purpose of this study is to evaluate the antiviral activity and safety of EntecaBell ODT. in chronic hepatitis B Patients.
- Trial name
- NCT02588937
- Testing
- EntecaBell ODT. 0.5mg, Baraclude Tab. 0.5mg
- Where
- 9 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Chong Kun Dang Pharmaceutical
HIV Infections
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of an antibody (called VRC01) in HIV-infected adults whose HIV was well-controlled with HIV medicines.
- Trial name
- NCT02463227
- Testing
- VRC01
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily and assess the safety in patients with hepatitis C virus infection compared to a placebo.
- Trial name
- NCT01258686
- Testing
- Silymarin
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Bukwang Pharmaceutical
Chronic Hepatitis C
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
This multicenter study was to evaluate subjects with chronic genotype 2 or 3 HCV infection who were interferon (IFN) ineligible, IFN intolerant or unwilling to take IFN.
- Trial name
- POSITRON (NCT01542788)
- Testing
- SOF, RBV
- Where
- 63 sites in United States, Australia and 3 more
- Volunteers
- 278 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis b
The Effect of Metabolic Syndrome on Antiviral Response in People With Chronic Hepatitis B
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major…
- Trial name
- NCT05705141
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Infection, Human Immunodeficiency Virus, HIV Infections
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen including FDA approved HIV drugs in HIV-infected pediatric subjects, ages 4 weeks to < 2 years…
- Trial name
- NCT00071760
- Testing
- GW433908, ritonavir
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 59 people
- Sponsor
- ViiV Healthcare
HIV Infections, Hepatitis C
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
This study will test the safety and effectiveness of a new treatment for hepatitis C (HCV) in patients who also have HIV. The usual treatment for HCV in people who are not HIV-infected is interferon-alfa (IFN) with ribavirin…
- Trial name
- NCT00015652
- Testing
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1.
- Trial name
- NCT01508130
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 672 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.